Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...
Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...
The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of ...
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...
NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
Top large-cap gainers for Dec. 15–19 were led by Rivian, Moderna, and BioMarin, rising on product/software updates, vaccine ...
As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...
Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups ...
The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p ...
Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast ...
Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...